Skip to main content

Tango Therapeutics, Inc 10-Q for FY2026 Q3

Tango Therapeutics, Inc. (TNGX)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Tango Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Tango Therapeutics reported an 82% ORR for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with MTAP-deleted/RAS-mutant PDAC and plans a global, randomized registrational trial in first-line PDAC in the first half of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $53.81M a year earlier
Net loss
$68.39M
compared with net income of $15.88M a year earlier
Diluted EPS
-$0.39
compared with $0.13 a year earlier